Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, P.R. China.
Biological Resource Center, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, P.R. China.
Oncogene. 2024 Mar;43(14):1019-1032. doi: 10.1038/s41388-024-02971-z. Epub 2024 Feb 16.
Breast cancer is one of the major malignant tumors among women worldwide. Long noncoding RNAs (lncRNAs) have been documented as significant modulators in the development and progression of various cancers; however, the contribution of lncRNAs to breast cancer remains largely unknown. In this study, we found a novel lncRNA (NONHSAT137675) whose expression was significantly increased in the breast cancer tissues. We named the novel lncRNA as lncRNA PRBC (PABPC1-related lncRNA in breast cancer) and identified it as a key lncRNA associated with breast cancer progression and prognosis. Functional analysis displayed that lncRNA PRBC could promote autophagy and progression of breast cancer. Mechanistically, we verified that lncRNA PRBC physically interacted with PABPC1 through RIP assay, and PABPC1 overexpression could reverse the inhibiting effect of lncRNA PRBC knockdown on the malignant behaviors in breast cancer cells. Knockdown of lncRNA PRBC interfered the translocation of PABPC1 from nucleus to cytoplasm as indicated by western blot and IF assays. Significantly, the cytoplasmic location of PABPC1 was required for the interaction between PABPC1 and AGO2, which could be enhanced by lncRNA PRBC overexpression, leading to strengthened recruitment of mRNA to RNA-induced silencing complex (RISC) and thus reinforcing the inhibition efficiency of miRNAs. In general, lncRNA PRBC played a critical role in malignant progression of breast cancer by inducing the cytoplasmic translocation of PABPC1 to further regulate the function of downstream miRNAs. This study provides novel insight on the molecular mechanism of breast cancer progression, and lncRNA PRBC might be a promising therapeutic target and prognostic predictor for breast cancer.
乳腺癌是全球女性中主要的恶性肿瘤之一。长链非编码 RNA(lncRNA)已被证明是多种癌症发展和进展的重要调节剂;然而,lncRNA 对乳腺癌的贡献在很大程度上仍然未知。在这项研究中,我们发现了一种新型 lncRNA(NONHSAT137675),其在乳腺癌组织中的表达显著增加。我们将新型 lncRNA 命名为 lncRNA PRBC(乳腺癌中与 PABPC1 相关的 lncRNA),并确定其为与乳腺癌进展和预后相关的关键 lncRNA。功能分析显示,lncRNA PRBC 可促进乳腺癌的自噬和进展。机制上,我们通过 RIP 测定验证了 lncRNA PRBC 与 PABPC1 物理相互作用,并且过表达 PABPC1 可以逆转 lncRNA PRBC 敲低对乳腺癌细胞恶性行为的抑制作用。lncRNA PRBC 的敲低干扰了 PABPC1 从核到细胞质的易位,如 western blot 和 IF 测定所示。重要的是,PABPC1 的细胞质定位是 PABPC1 与 AGO2 之间相互作用所必需的,lncRNA PRBC 的过表达可以增强这种相互作用,从而导致更多的 mRNA 募集到 RNA 诱导的沉默复合物(RISC),从而增强 miRNAs 的抑制效率。总的来说,lncRNA PRBC 通过诱导 PABPC1 的细胞质易位在乳腺癌的恶性进展中发挥关键作用,进而调节下游 miRNAs 的功能。本研究为乳腺癌进展的分子机制提供了新的见解,lncRNA PRBC 可能是乳腺癌有前途的治疗靶点和预后预测因子。